Drug Trial Radar · NCT01560286
A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks
Last checked: Nov 20, 2026Latest source record: Aug 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
May 2012
Primary completion
Sep 2013
Study completion Jul 2015
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Mar 22, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the effect of dosing regimens of multiple subcutaneous (SC) doses of rAvPAL-PEG to induce an early and sustained Phe reduction while decreasing the frequency and severity of hypersensitivity reactions in patients with PKU.
Conditions
- Phenylketonuria
Interventions
BMN 165 (rAvPAL-PEG)Biological
Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood Phenylalanine ConcentrationTime frame: Baseline, Week 24
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
The Children's Hospital
Aurora, Colorado
University of Florida, Gainesville
Gainesville, Florida
Children's Hospital Boston
Boston, Massachusetts
Nebraska Medical Center
Omaha, Nebraska
Albany Medical Center
Albany, New York
University of Utah Hospital
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.